We investigated the response of glucagon and other counterregulatory hormones, insulin and C-peptide concentration, hypoglycemic symptoms, and cognitive function during clamp-induced hypoglycemia in people with T2D treated with tirzepatide versus placebo. The gene discussed is GCG; the disease is type 2 diabetes mellitus.